Blood test for Alzheimer's: Study identifies procedure that detects early stages

(Medical Xpress) -- A new blood test that will diagnose Alzheimer's disease may soon hit the market, thanks to an innovative study from the Research Institute of the McGill University Health Centre (MUHC). Their findings have characterized a unique biochemical diagnosis, which identifies patients with this devastating disorder. This research, published in the month's issue of the Journal of Alzheimer's Disease, has implications for the half-a-million Canadian sufferers and many millions more worldwide.

"Until now, there has been no definitive for Alzheimer's, other than postmortem analysis of ," says senior author Dr. Vassilios Papadopoulos, director of the MUHC Research Institute. "Our clinical study shows that a non-invasive , based on a biochemical process, may be successfully used to diagnose Alzheimer's at an early stage and differentiate it from other types of ."

The biochemistry behind the test

Papadopoulos and colleagues based the Alzheimer's blood test on the production of a brain hormone called dehydroepiandrosterone (DHEA). This hormone is present at high levels in the brain where it has a wide range of biological effects.

The researchers were able to promote the production of DHEA, using a chemical process called oxidation, in blood taken from non-Alzheimer's patients. However, oxidation of blood from Alzheimer's patients did not result in an increase of DHEA.

"There is a clear correlation between the lack of ability to produce DHEA through in the blood and the degree of found in Alzheimer's disease," says Papadopoulos. "We demonstrated we could accurately and repetitively detect Alzheimer's disease, with small samples of blood. This test also allowed for differential diagnosis of early stages of Alzheimer's disease, suggesting this can be used as a test to diagnose the disease in its infancy."

Treatment implications

"There are many candidate disease-modifying therapies that target the underlying development of , which are in clinical trials," adds Papadopoulos. "However, the implementation of any therapy is dependant on the reliability of the diagnosis."

Currently the diagnosis of Alzheimer's follows the sequence of family history, information, mental assessment and the physical exam, focusing on neurological signs.

"An accurate, easy and specific non-invasive biochemical test that correlates with clinical findings is vital. We believe our results demonstrate that the DHEA-oxidation blood test can be used to diagnose Alzheimer's at a very early stage and monitor the effect of therapies and the evolution of the disease."

More information: A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: The biochemical basis for a diagnosis of Alzheimer's disease, Journal of Alzheimer's Disease. www.j-alz.com/

Related Stories

Blood test could diagnose Alzheimer's disease

Oct 05, 2010

A set of proteins found in blood serum shows promise as a sensitive and accurate way to diagnose Alzheimer's disease, researchers at UT Southwestern Medical Center have found as part of a statewide study.

New technique opens door to early Alzheimer's diagnosis

Jun 16, 2009

A new diagnostic technique which may greatly simplify the detection of Alzheimer's disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's ...

Investigating the causes of Alzheimer's

Nov 22, 2007

Scientists at the University of Bristol are investigating what causes the leaks that develop in blood vessels in Alzheimer's disease, thanks to funding from the UK's leading dementia research charity, the Alzheimer's Research ...

Recommended for you

User comments